Quarterly report pursuant to Section 13 or 15(d)

Acquisitions, Investments and Licenses - Transition Therapeutics Purchase Price Allocation (Details)

v3.8.0.1
Acquisitions, Investments and Licenses - Transition Therapeutics Purchase Price Allocation (Details) - USD ($)
$ in Thousands
Sep. 30, 2017
Dec. 31, 2016
Aug. 31, 2016
Business Acquisition [Line Items]      
Goodwill $ 715,573 $ 704,603  
Transition Therapeutics      
Business Acquisition [Line Items]      
Cash and cash equivalents     $ 15,878
Goodwill     3,453
Other assets     634
Accounts payable and other liabilities     (1,035)
Deferred tax liability     (1,400)
Total purchase price     58,530
In Process Research and Development | Transition Therapeutics      
Business Acquisition [Line Items]      
IPR&D assets     $ 41,000